Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect of Vitamin C, Vitamin D and Zinc Supplementation on the Immune and Inflammatory Process in Type 2 Diabetic Subjects in Mexico
Verified date | November 2018 |
Source | Universidad Autonoma del Estado de Mexico |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Type 2 Diabetes Mellitus According to the World Health Organization (WHO), there are more
than 346 million individuals with diabetes, of which 90% are type 2. Global estimations for
the year 2030 predict an epidemic increase that will reach 366 million. According to the
National Nutrition and Health Survey of 2006 (ENSANUT2005), there are 6.4 million type 2
diabetic subjects in Mexico.
According to the calculation of the sample size, the investigators will include 120 adults
with type 2 diabetes mellitus selected from the outpatient preventive medicine offices of
health centres in the State of Mexico who will divided in two groups: supplement and placebo
(60 per group). After having been invited to participate and obtaining the informed consent,
study subjects will be evaluated for dietary information, as well as biochemical biomarkers
of metabolic control, anthropometric, immune and inflammatory markers, gut microbiota and
oxidative stress, before beginning the trial, and after 12 and 24 weeks of supplementation.
They will have a monthly follow-up visit for evaluation of adherence and adverse effects, as
well as delivery of the supplement.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | March 26, 2020 |
Est. primary completion date | January 9, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Between 25 and 55 years of age, as this is the age in which type 2 diabetes mellitus is more prevalent and there is less probability of encountering multiple diseases in the same subjects - Both sexes - Outpatients - BMI = 25 Exclusion Criteria: - Without any other chronic disease (cancer, cardiovascular diseases, arthritis and Alzheimer's). - Severe renal insufficiency. - Nephrolithiasis or history of nephrolithiasis. - Hyperoxaluria. - Hemochromatosis. - Hypercalcaemia. - Hypervitaminosis D. - Using insulin. - Be taking drugs such as desferrioxamine, iron, cyclosporine, indinavir (protease inhibitors), warfarin, thiazide diuretic, orlistat, ion exchange resins (e.g cholestyramine, laxatives (e.g. mineral oil, senna), vitamin d analogues (e.g. ergocalciferol, calcitriol, and topical calcipotriene), tetracycline antibiotics, quinolone antibiotics, penicillamine, biphosphonates, levothyroxine, eltrombopag. - Patients with hypersensitivity to any of the active substance(s) or to any of the excipients. - Hypersensitivity to the by-products including honey, conifers, poplars, Peru balsam, and salicylate. - Intake of probiotics or supplemental vitamin or mineral (vitamin D, C, zinc or calcium) for 4 weeks before the beginning of the study. - Smoking and alcohol consumption (> 40 gr/ day for men and 25 gr/ day for women. - Pregnant or lactating. - Whose parents or grandparents are/were immigrant or of native origin. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Universidad Autonoma del Estado de Mexico |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in plasma vitamin C from baseline to 12 and 24 weeks | Measured with a Colorimetric assay, in mg/dL | Baseline, 12 and 24 weeks | |
Other | Changes in plasma vitamin D from baseline to 12 and 24 weeks | Measured with a commercial ELISA kit, ng/mL | Baseline, 12 and 24 weeks | |
Other | Changes in plasma zinc from baseline to 12 and 24 weeks | Measured with a Colorimetric assay, in mg/dL | Baseline, 12 and 24 weeks | |
Primary | Change in glycemia from baseline to 12 and 24 weeks | Measured in plasma with a Selectra II automated equipment with Randox reactants, in mg/dL | Baseline, 12 and 24 weeks | |
Primary | Change in glycosilated Hemoglobin (Hb1Ac) from baseline to 12 and 24 weeks | Measured in plasma with a Selectra II automated equipment with Randox reactants, in percentage | Baseline, 12 and 24 weeks | |
Primary | Change in plasma insulin from baseline to 12 and 24 weeks | Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in uU/mL | Baseline, 12 and 24 weeks | |
Primary | Change in Homeostatic Model Assesment for Insulin Resistance (HOMA-IR) from baseline to 12 and 24 weeks | Calculated from: HOMA-IR = (insulin x glucose)/405 | Baseline, 12 and 24 weeks | |
Secondary | Change in plasma cytokines from baseline to 12 and 24 weeks | Tumor Necrosis Factor alfa (TNFa), Interferon gamma (IFN-?), Interleukins 1 beta, 4, 6 and 10 (IL-1ß, IL4, IL-6, IL10) & transforming growth factor beta (TGF-ß), measured with Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in pg/mL | Baseline, 12 and 24 weeks | |
Secondary | Change in plasma adipokines from baseline to 12 and 24 weeks | Adiponectin, resistin and leptin, measured with Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in pg/mL | Baseline, 12 and 24 weeks | |
Secondary | Change in additional plasma inflammatory markers from baseline to 12 and 24 weeks | Apolipoproteins A and B, C-reactive protein, vascular cell adhesion protein (V-CAM), intercellular adhesion molecule (I-CAM), complement proteins C-3 and C-4, measured with Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in pg/mL | Baseline, 12 and 24 weeks | |
Secondary | Change in lipid profile from baseline to 12 and 24 weeks | Total cholesterol, HDL-, LDL-, Very Low Density Lipoprotein (VLDL)-cholesterol and triacylglycerides, measured in plasma with a Selectra II automated equipment with Randox reactants, in mg/dL | Baseline, 12 and 24 weeks | |
Secondary | Changes in markers of oxidative stress from baseline to 12 and 24 weeks | Malondialdehyde (QuantiChromTM), Thiobarbituric acid reactive substances (TBARS Assay Kit), carbonylated proteins (colorimetric), antioxidant capacity (QuantiChromTM Antioxidant Assay Kit), catalase (EnzyChromTM Catalase Assay Kit), superoxide dismutase (EnzyChromTM Superoxide Dismutase Assay Kit) and glutathion peroxidase (metaphosphoric acid SIGMA ALDRICH y EnzyChromTM GSH/GSSG Assay Kit, measured with various commercial kits, in U/µL | Baseline, 12 and 24 weeks | |
Secondary | Changes in lymphocyte subpopulations from baseline to 12 and 24 weeks | Cluster of desgination 4, 8, 17 and 19 (CD4+, CD8+, CD17+ and CD19+), measured by flow cytometry (Becton Dickinson Facs AriaMR de 6 canales), in percentage | Baseline, 12 and 24 weeks | |
Secondary | Changes in Intestinal microbiota patterns from baseline to 12 and 24 weeks | Analyzed with a Illumina sequencing equipment and Mothur y Stamp softwares, in percentage | Baseline, 12 and 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |